Effect of feeding mode on infant growth and cognitive function: study protocol of the Chilean infant Nutrition randomized controlled Trial (ChiNuT)

Simple item page
dc.contributor.authorToro Campos, Rosario.
dc.contributor.authorPeña, Marcela
dc.contributor.authorUauy, Ricardo
dc.contributor.authorAlgarín, Cecilia.
dc.contributor.authorPeirano, Patricio.
dc.contributor.authorMurguia-Peniche, Teresa.
dc.contributor.authorWu, Steven S.
dc.date.accessioned2020-06-01T16:12:28Z
dc.date.available2020-06-01T16:12:28Z
dc.date.issued2020
dc.date.updated2020-05-26T11:02:07Z
dc.description.abstractAbstract Background A central aim for pediatric nutrition is to develop infant formula compositionally closer to human milk. Milk fat globule membranes (MFGM) have shown to have functional components that are found in human milk, suggesting that addition of bovine sources of MFGM (bMFGM) to infant formula may promote beneficial outcomes potentially helping to narrow the gap between infants who receive human breast milk or infant formula. The objective of the current study is to determine how the addition of bMFGM in infant formula and consumption in early infancy affects physical growth and brain development when compared to infants fed with a standard formula and a reference group of infants fed with mother’s own milk. Methods Single center, double-blind, and parallel randomized controlled trial. Planned participant enrollment includes: infants exclusively receiving breast milk (n = 200; human milk reference group; HM) and infants whose mothers chose to initiate exclusive infant formula feeding before 4 months of age (n = 340). The latter were randomized to receive one of two study formulas until 12 months of age: 1) cow’s milk based infant formula that had docosahexaenoic (DHA) (17 mg/100 kcal) and arachidonic acid (ARA) (25 mg/100 kcal); 1.9 g protein/100 kcal; 1.2 mg Fe/100 kcal (Standard formula; SF) or 2) a similar infant formula with an added source of bovine MFGM (whey protein-lipid concentrate (Experimental formula; EF). Primary outcomes will be: 1) Physical growth (Body weight, length, and head circumference) at 730 days of age; and 2) Cognitive development (Auditory Event-Related Potential) at 730 days of age. Data will be analyzed for all participants allocated to each study feeding group. Discussion The results of this study will complement the knowledge regarding addition of bMFGM in infant formula including support of healthy growth and improvement of neurodevelopmental outcomes. Trial registration NCT02626143, registered on December 10th 2015.Abstract Background A central aim for pediatric nutrition is to develop infant formula compositionally closer to human milk. Milk fat globule membranes (MFGM) have shown to have functional components that are found in human milk, suggesting that addition of bovine sources of MFGM (bMFGM) to infant formula may promote beneficial outcomes potentially helping to narrow the gap between infants who receive human breast milk or infant formula. The objective of the current study is to determine how the addition of bMFGM in infant formula and consumption in early infancy affects physical growth and brain development when compared to infants fed with a standard formula and a reference group of infants fed with mother’s own milk. Methods Single center, double-blind, and parallel randomized controlled trial. Planned participant enrollment includes: infants exclusively receiving breast milk (n = 200; human milk reference group; HM) and infants whose mothers chose to initiate exclusive infant formula feeding before 4 months of age (n = 340). The latter were randomized to receive one of two study formulas until 12 months of age: 1) cow’s milk based infant formula that had docosahexaenoic (DHA) (17 mg/100 kcal) and arachidonic acid (ARA) (25 mg/100 kcal); 1.9 g protein/100 kcal; 1.2 mg Fe/100 kcal (Standard formula; SF) or 2) a similar infant formula with an added source of bovine MFGM (whey protein-lipid concentrate (Experimental formula; EF). Primary outcomes will be: 1) Physical growth (Body weight, length, and head circumference) at 730 days of age; and 2) Cognitive development (Auditory Event-Related Potential) at 730 days of age. Data will be analyzed for all participants allocated to each study feeding group. Discussion The results of this study will complement the knowledge regarding addition of bMFGM in infant formula including support of healthy growth and improvement of neurodevelopmental outcomes. Trial registration NCT02626143, registered on December 10th 2015.
dc.identifier.citationBMC Pediatrics. 2020 May 18;20(1):225
dc.identifier.doi10.1186/s12887-020-02087-9
dc.identifier.urihttps://doi.org/10.1186/s12887-020-02087-9
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/29282
dc.issue.numeroNo. 225
dc.language.isoen
dc.pagina.final11
dc.pagina.inicio1
dc.revistaBMC Pediatricses_ES
dc.rightsacceso abierto
dc.rights.holderThe Author(s)
dc.subjectInfant formulaes_ES
dc.subjectMilk fat globule membranees_ES
dc.subjectMFGMes_ES
dc.subjectGrowth and developmentes_ES
dc.subjectClinical trialses_ES
dc.subjectBreast feedinges_ES
dc.subjectChilees_ES
dc.subject.ddc612.65
dc.subject.deweyMedicina y saludes_ES
dc.titleEffect of feeding mode on infant growth and cognitive function: study protocol of the Chilean infant Nutrition randomized controlled Trial (ChiNuT)es_ES
dc.typeartículo
dc.volumenVol. 20
sipa.codpersvinculados1010950
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12887_2020_Article_2087.pdf
Size:
574.73 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos de revistas